Acinetobacter Baumannii, Pneumonitis
Conditions
Keywords
Eravacycline
Brief summary
This study intends to evaluate the efficacy and safety of eravacycline-based combination therapy in real words for Chinese patients with CRAB pneumonia, providing data reference for clinical treatment of CRAB pneumonia.
Detailed description
This study aims to include 50 patients proven or suspected diagnosed carbapenem-resistant Acinetobacter baumannii pneumonia at Peking University Third Hospital. The physician determines to use a combination regimen of eravacycline, including sulbactam or compound preparations containing sulbactam, polymyxin B, and β-lactam antibiotics, is considered. The clinical response rate at the end of treatment is the primary endpoint of the study; the secondary endpoints include the clearance rate of carbapenem-resistant Acinetobacter baumannii, the incidence of adverse events, and the all-cause mortality rate within 28 days.
Interventions
DRUGEravacycline combination therapy group
Physicians determine the combination regimen of eravacycline, which may include sulbactam or compound preparations containing sulbactam, polymyxin B, beta-lactam antibiotics, etc., based on the pathogen identification and susceptibility results, and the China Guidelines for Diagnosis, Treatment, and Prevention of Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria. The combined drugs are used according to their instructions for use or clinical practice guidelines.
Sponsors
Peking University Third Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Aged 18 years or older. 2. Voluntarily participating in this study and signing an informed consent form. If the subject is unable to read and/or sign the informed consent form due to lack of capacity or other reasons, the informed process and the informed consent form must be signed by their legal guardian. 3. Patients with clinical manifestations and imaging results consistent with bacterial pneumonia, and who are expected to benefit from antimicrobial treatment. Suspected carbapenem-resistant Acinetobacter baumannii infection or Acinetobacter baumannii detected in two consecutive sputum cultures (at least one of which must be from bronchoalveolar lavage or endotracheal aspirate), with resistance to carbapenems. 4. Patients who have been treated with eravacycline for at least 3 days.
Exclusion criteria
1. The investigator believes that there are any medical history, current condition, treatment, abnormal laboratory test results, or other situations that may affect the trial results, interrupt the trial process (or the subject cannot complete all trial requirements, operations, and visits), or increase the risk to the subject from receiving the trial medication, including patients with terminal illness, or evidence of an immediately life-threatening disease. 2. Patients with a history of allergic reactions to tetracyclines or any excipients contained in the formulation of the study medication.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| clinical efficacy at the end of treatment | up to the end of treatment, up to 4 weeks(estimation) | The primary endpoint is the clinical efficacy at the end of treatment (within 24 hours after the last dose of the trial medication) for all patients who have completed the trial according to the protocol. Clinical efficacy is assessed and the clinical response rate is calculated. Clinical response is evaluated by PI，and defined as an improvement, reduction, or disappearance of the patient's multiple symptoms and signs compared to before treatment, along with improvement or normalization of imaging findings. Clinical response rate = (number of patients with symptom relief) / (total number of patients included in the study). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence Rate of Adverse Event | up to the end of treatment, up to 4 weeks(estimation) | safety data according to CTC-AE |
| The microbiological clearance rate | up to the end of treatment, up to 4 weeks(estimation) | The microbiological clearance rate is at the end of treatment |
| The all cause mortality rate | 28 days | The all-cause mortality rate within 28 days |
Countries
China
Contacts
Primary ContactWang Fei, doctor
Outcome results
None listed